Cholesterol drug maker pays $4.1 million to settle fraud charges: SEC

WASHINGTON (Reuters) - Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, will pay $4.1 million to settle charges it misled investors about how many patients purchased Juxtapid, a drug used to treat a genetic condition that leads to high cholesterol, the top U.S. securities regulator said on Friday.